Teva Pharmaceutical Industries Is Turning A Corner (NYSE:TEVA) | Seeking Alpha
Key concepts and critical issues on epoetin and filgrastim biosimilars. A position paper from the Italian Society of Hematology, Italian Society of Experimental Hematology, and Italian Group for Bone Marrow Transplantation
PDF] Multidisciplinary approach to evaluating immunogenicity of biosimilars: lessons learnt and open questions based on 10 years' experience of the European Union regulatory pathway | Semantic Scholar
Comparison of PBSC mobilized by either the biosimilar XM02... | Download Scientific Diagram
Are biosimilars following the same pattern as generics? Neupogen keeps just 6% of the EU market after 10 years
Earnings Preview: What To Expect From Teva Pharmaceutical On Monday
Real-world safety experience of tevagrastim/ratiograstim/biograstim and tbo-filgrastim, short-acting recombinant human granulocyte colony-stimulating factors | Request PDF
TEVA - Annual Report (10-k)
Ratiograstim® 48 Mio. I.E./0,8 ml Injektions- oder Infusionslösung - ratiopharm GmbH